Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "gene- therapy" wg kryterium: Wszystkie pola


Tytuł:
Helper-dependent adenoviral vectors in experimental gene therapy
Autorzy:
Józkowicz, Alicja
Dulak, Józef
Powiązania:
https://bibliotekanauki.pl/articles/1041362.pdf
Data publikacji:
2005
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
helper-dependent adenoviral vectors
adenoviruses
gene therapy
Opis:
In the majority of potential applications gene therapy will require an effective transfer of a transgene in vivo resulting in high-level and long-term transgene expression, all in the absence of significant toxicity or inflammatory responses. The most efficient vehicles for delivery of foreign genes to the target tissues are modified adenoviruses. Adenoviral vectors of the first generation, despite the high infection efficacy, have an essential drawback: they induce strong immune response, which leads to short term expression of the transgene, and limits their usefulness in clinical trials. In contrast, helper-dependent adenoviral vectors (HdAd) lacking all viral coding sequences display only minimal immunogenicity and negligible side-effects, allowing for long-term transgene expression. Thus, HdAd vehicles have become the carrier of choice for adenoviral vector-mediated experimental gene therapy, effectively used in animal models for delivery of transgenes into the liver, skeletal muscle, myocardium or brain. Strong and long-lasting expression of therapeutic genes has allowed for successful treatment of dyslipidemias, muscular dystrophy, obesity, hemophilia, and diabetes. Additionally, the large cloning capacity of HdAd, up to 37 kb, facilitates the use of physiologically regulated, endogenous promoters, instead of artificial viral promoter sequences. This enables also generation of the single vectors expressing multiple genes, which can be potentially useful for treatment of polygenic diseases. In this review we characterize the basic features of HdAd vectors and describe some of their experimental and potential clinical applications.
Źródło:
Acta Biochimica Polonica; 2005, 52, 3; 589-599
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
IGF-I: from diagnostic to triple-helix gene therapy of solid tumors.
Autorzy:
Trojan, Ladislas
Kopinski, Piotr
Wei, Ming
Ly, Adama
Glogowska, Aleksandra
Czarny, Jolanta
Shevelev, Alexander
Przewlocki, Ryszard
Henin, Dominique
Trojan, Jerzy
Powiązania:
https://bibliotekanauki.pl/articles/1043704.pdf
Data publikacji:
2002
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
glioblastoma
tumors
antisense
triple-helix
IGF-I
gene therapy
Opis:
Alterations in the expression of growth factors and their receptors are associated with the growth and development of human tumors. One such growth factor is IGF-I (insulin-like growth factor I ), a 70-amino-acid polypeptide expressed in many tissues, including brain. IGF-I is also expressed at high levels in some nervous system-derived tumors, especially in glioblastoma. When using IGF-I as a diagnostic marker, 17 different tumors are considered as expressing the IGF-I gene. Malignant glioma, the most common human brain cancer, is usually fatal. Average survival is less than one year. Our strategy of gene therapy for the treatment of gliomas and other solid tumors is based on: 1) diagnostic using IGF-I gene expression as a differential marker, and 2) application of "triple-helix anti-IGF-I " therapy. In the latter approach, tumor cells are transfected with a vector, which encodes an oligoribonucleotide - an RNA strand containing oligopurine sequence which might be capable of forming a triple helix with an oligopurine and/or oligopyrimidine sequence of the promotor of IGF-I gene (RNA-IGF-I DNA triple helix). Human tumor cells transfected in vitro become down-regulated in the production of IGF-I and present immunogenic (MHC-I and B7 expression) and apoptotic characteristics. Similar results were obtained when IGF-I antisense strategy was applied. In both strategies the transfected cells reimplanted in vivo lose tumorigenicity and elicit tumor specific immunity which leads to elimination of established tumors.
Źródło:
Acta Biochimica Polonica; 2002, 49, 4; 979-990
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Preparaty siRNA w terapii genowej raka jajnika
siRNA preparations in gene therapy of ovarian cancer
Autorzy:
Pankowska, Magdalena
Stachurska, Anna
Woźniak, Małgorzata
Małecki, Maciej
Powiązania:
https://bibliotekanauki.pl/articles/1031566.pdf
Data publikacji:
2014
Wydawca:
Medical Communications
Tematy:
sirna
rak jajnika
terapia genowa
badania kliniczne
chemiooporność
ovarian cancer
gene therapy
clinical research
chemoresistance
Opis:
According to statistics, ovarian cancer is the fourth cause of death due to gynecologic cancer. It results from late diagnosis of the disease, caused by the lack of characteristic symptoms, as well as from unsatisfactory treatment methods due to e.g. cell resistance to chemotherapy. The search for new therapies is still in progress. It is believed that preparations whose activity is based on RNA interference, i.e. gene silencing with the use of siRNA, are a promising group of new antineoplastic medications. Fire et al. were awarded the Nobel Prize for discovering this phenomenon. The phenomenon of siRNA interference in healthy cells is a natural protective mechanism. Genes are silenced in the cytoplasm with the use of the Dicer enzyme. siRNA gene preparations are delivered into cells with the use of viral methods such as AAV or adenoviruses, as well as non-viral methods e.g. with the use of liposomes. Clinical trials concerning siRNA preparations are now in the first phase. They are conducted on two gene preparations: CALAA-01 and siRNA nanomolecule directed against PLK1. In this paper attention was drawn to the therapeutic meaning of siRNA sequences in relation to the following genes: MDR1, VEGF, MMP, CD44, HER2, SHH, STAT. Both experimental and clinical studies give hope for the use of the described mechanisms in fight with ovarian cancer in the future.
Rak jajnika według statystyk zajmuje czwarte miejsce wśród zgonów z powodu nowotworów ginekologicznych. Wynika to zarówno z późnego rozpoznania choroby, spowodowanego brakiem charakterystycznych objawów, jak i stale niezadowalających efektów leczenia, m.in. ze względu na oporność komórek na chemioterapię. Poszukiwanie nowych metod terapii jest więc nadal aktualne. Uważa się, że obiecującą grupą potencjalnych leków przeciwnowotworowych mogą być preparaty, których aktywność opiera się na zjawisku interferencji RNA, czyli wyciszaniu genów za pomocą siRNA. Za odkrycie tego zjawiska Fire i wsp. zostali uhonorowani Nagrodą Nobla. Zjawisko interferencji siRNA w prawidłowych komórkach jest naturalnym mechanizmem obronnym. Do wyciszenia genów dochodzi w cytoplazmie przy udziale enzymu Dicer. Preparaty genowe siRNA wprowadza się do komórek, wykorzystując metody wirusowe, takie jak AAV czy adenowirusy, a także za pomocą metod niewirusowych, np. z zastosowaniem liposomów. Badania kliniczne preparatów genowych siRNA znajdują się obecnie w pierwszej fazie. Prowadzone są na dwóch preparatach genowych CALAA-01 oraz na nanocząsteczce siRNA skierowanej przeciw PLK1. W niniejszej pracy skupiono uwagę na terapeutycznym znaczeniu sekwencji siRNA w stosunku do genów: MDR1, VEGF, MMP, CD44, HER2, SHH, STAT. Zarówno badania eksperymentalne, jak i kliniczne niosą nadzieję na wykorzystanie w przyszłości omawianego mechanizmu do walki z rakiem jajnika.
Źródło:
Current Gynecologic Oncology; 2014, 12, 3; 197-205
2451-0750
Pojawia się w:
Current Gynecologic Oncology
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Combination of vasostatin gene therapy with cyclophosphamide inhibits growth of B16(F10) melanoma tumours
Autorzy:
Jazowiecka-Rakus, Joanna
Jarosz, Magdalena
Szala, Stanisław
Powiązania:
https://bibliotekanauki.pl/articles/1041289.pdf
Data publikacji:
2006
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
angiogenesis
combination
vasostatin
cyclophosphamide
gene therapy
Opis:
Angiogenesis, i.e. formation of new blood vessels out of pre-existing capillaries, is essential to the development of tumour vasculature. The discovery of specific antiangiogenic inhibitors has important therapeutic implications for the development of novel cancer treatments. Vasostatin, the N-terminal domain of calreticulin, is a potent endogenous inhibitor of angiogenesis and tumour growth. In our study, using B16(F10) murine melanoma model and electroporation we attempted intramuscular transfer of human vasostatin gene. The gene therapy was combined with antiangiogenic drug dosing schedule of a known chemotherapeutic (cyclophosphamide). The combination of vasostatin gene therapy and cyclophosphamide administration improved therapeutic effects in melanoma tumours. We observed both significant inhibition of tumour growth and extended survival of treated mice. To our knowledge, this is one of the first reports showing antitumour efficacy of electroporation-mediated vasostatin gene therapy combined with antiangiogenic chemotherapy.
Źródło:
Acta Biochimica Polonica; 2006, 53, 1; 199-202
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Construction of a bicistronic proangiogenic expression vector and its application in experimental angiogenesis in vivo.
Autorzy:
Małecki;, Maciej
Przybyszewska, Małgorzata
Janik, Przemysław
Powiązania:
https://bibliotekanauki.pl/articles/1043468.pdf
Data publikacji:
2003
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
angiogenesis
gene therapy
bicistronic vectors
Opis:
Manipulation of angiogenesis in vivo is an example of successful gene therapy strategies. Overexpression of angiogenic genes like VEGF, FGF or PDGF causes new vessel formation and improves the clinical state of patients. Gene therapy is a very promising procedure but requires large amounts of pharmaceutical-grade plasmid DNA. In this regard we have constructed a bicistronic plasmid DNA vector encoding two proangiogenic factors, VEGF165 and FGF-2. The construct (pVIF) contains the internal ribosome entry site (IRES) of the encephalomyocarditis virus (ECMV) which permits both genes to be translated from a single bicistronic mRNA. The IRES sequence allows for a high efficiency of gene expression in vivo. The pVIF vector was characterized in vitro and in vivo. In vivo angiogenesis studies showed that the bicistronic vector encoding two proangiogenic factors induces the formation of new vessels significantly more than pVEGF165 or pFGF-2 alone. In our opinion the combined proangiogenic approach with VEGF165 and FGF-2 is more powerful and efficient than single gene therapy. We also postulate that IRES sequence can serve as a useful device improving efficiency of gene therapy.
Źródło:
Acta Biochimica Polonica; 2003, 50, 3; 875-882
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Charakterystyka nanostrukturalna materiału genetycznego do zastosowania w terapii genowej
Nanostructural characteristics of genetic material for gene therapy application
Autorzy:
Duda, M.
Frączkowska, K.
Przybyło, M.
Kopaczyńska, M.
Powiązania:
https://bibliotekanauki.pl/articles/261139.pdf
Data publikacji:
2015
Wydawca:
Politechnika Wrocławska. Wydział Podstawowych Problemów Techniki. Katedra Inżynierii Biomedycznej
Tematy:
kondensacja DNA
spermidyna
terapia genowa
mikroskopia sił atomowych
DNA condensation
spermidine
gene therapy
atomic force microscopy (AFM)
Opis:
Terapia genowa jest obecnie bardzo dynamicznie rozwijającą się techniką biomedyczną, która może znaleźć zastosowanie w medycynie w leczeniu chorób przewlekłych i dziedzicznych. Badania skupiają się na opracowywaniu nowych strategii dotyczących procesów kondensacji i ochrony materiału genetycznego (DNA) wprowadzanego do komórki docelowej. Struktura i stopień upakowania dostarczanego DNA wpływają na kluczowe właściwości fizykochemiczne, determinujące czy wprowadzony wektor rekombinowany ulegnie ekspresji, czy też degradacji. Związki chemiczne, zwane czynnikami kondensującymi, to substancje powodujące zwinięcie DNA, a stopień kondensacji materiału genetycznego zależy bezpośrednio od rodzaju i stężenia użytego czynnika kondensującego. Do cząsteczek wykazujących właściwości kondensujące należą poliaminy, w opisywanym eksperymencie zastosowano poliaminę – spermidynę. Przeprowadzone badania miały na celu charakterystykę nanostrukturalną materiału genetycznego pod wpływem działania czynnika kondensującego. W wyniku analizy wykonanej za pomocą mikroskopii sił atomowych (AFM) wykazano, że plazmid DNA ulega kondensacji pod wpływem spermidyny, formując struktury rozetowe.
Gene therapy is a new promising method that may find many applications in modern biomedicine. Especially, it may be a powerful tool in chronic and hereditary diseases treatment. Current studies focus on development of novel strategies concerning genetic material (DNA) condensation and protection, whilst it is introduced into the cellular nucleus. Once the DNA enters the cell, it’s either passed on and expressed in the nucleus or degraded by intracellular nucleases. The structure and the degree of compaction influence physicochemical properties that determine what will happen to delivered genetic material. DNA coiling can be caused by chemical compounds called compaction agents, such as polyamines like spermidine used in this study. The aim of this research was to examine the nanostructural characteristics of genetic material exposed to compaction agent. The measurements and analysis performed by atomic force microscopy (AFM) indicate that DNA plasmid undergoes condensation and forms rosette-like structures once subjected to spermidine.
Źródło:
Acta Bio-Optica et Informatica Medica. Inżynieria Biomedyczna; 2015, 21, 1; 1-8
1234-5563
Pojawia się w:
Acta Bio-Optica et Informatica Medica. Inżynieria Biomedyczna
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Newest therapeutic options for adrenoleukodystrophy
Autorzy:
Gołębiowska, Maria
Gołębiowska, Beata
Beń-Skowronek, Iwona
Powiązania:
https://bibliotekanauki.pl/articles/1163988.pdf
Data publikacji:
2018
Wydawca:
Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
Tematy:
X-ALD
adrenoleukodystrophy
gene therapy
neurodegenerative disorders
Opis:
X-linked adrenoleukodystrophy is a genetic disease correlated with mutation of ATP-binding cassette, which results in errors of peroxisomal beta oxidation and accumulation of impaired very long chain fatty acids. This leads to degeneration of adrenal glands, spinal cord and myelin sheaths. Despite nearly 100 years of ALD history, the treatment is limited to few therapeutic options, mainly Lorenzo’s Oil and Hematopoetic stem cell transplant. Available therapy can only slow the progression of the disease in early stages. The aim of our study was to present the newest therapeutic options in X-ALD. Substantial articles on new treatment of X-ALD from period 2007-2018 in the Asian, European and American regions have been analyzed. Among 219 articles in PubMed Medline database related to therapy and treatment of X-ALD, 13 articles were selected for analysis, reviewed and divided into two main groups: cause-related treatment (11 articles) and symptoms-related treatment (2 articles). Within cause-related treatment, the usage of known medications such as eg. pioglitazone, natural phenols - resveratrol, gene therapy with adenoassociated virus serotype 9 or combined therapies (Hematopoetic Stem Cell Gene Therapy) have been reviewed. Symptoms related treatment attempted to reduce spasticity and secondary dystonia in X-ALD patients. Reviewed research presents progress in development of treatment options for X-ALD, however still in primary in vitro and animal tested stages. Secondary neurological symptoms medication is awaiting for better solutions for ALD patients, in order to improve their Quality of Life and allow symptomless course for a longer time.
Źródło:
World Scientific News; 2018, 108; 133-143
2392-2192
Pojawia się w:
World Scientific News
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Cancer immunotherapy using cells modified with cytokine genes.
Autorzy:
Kowalczyk, Dariusz
Wysocki, Piotr
Mackiewicz, Andrzej
Powiązania:
https://bibliotekanauki.pl/articles/1043434.pdf
Data publikacji:
2003
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
cancer
cancer vaccines
cytokines
dendritic cells
gene therapy
Opis:
The ability of various cytokines to hamper tumor growth or to induce anti-tumor immune response has resulted in their study as antitumor agents in gene therapy approaches. In this review we will concentrate on the costimulation of antitumor immune responses using modification of various cell types by cytokine genes. Several strategies have emerged such as (i) modification of tumor cells with cytokine genes ex vivo (whole tumor cell vaccines), (ii) ex vivo modification of other cell types for cytokine gene delivery, (iii) delivery of cytokine genes into tumor microenvironment in vivo, (iv) modification of dendritic cells with cytokine genes ex vivo. Originally single cytokine genes were used. Subsequently, multiple cytokine genes were applied simultaneously, or in combination with other factors such as chemokines, membrane bound co-stimulatory molecules, or tumor associated antigens. In this review we discuss these strategies and their use in cancer treatment as well as the promises and limitations of cytokine based cancer gene therapy. Clinical trials, including our own experience, employing the above strategies are discussed.
Źródło:
Acta Biochimica Polonica; 2003, 50, 3; 613-624
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Adeno-associated virus vector-mediated gene delivery to the vasculature and kidney.
Autorzy:
Kapturczak, Matthias
Chen, Sifeng
Agarwal, Anupam
Powiązania:
https://bibliotekanauki.pl/articles/1041403.pdf
Data publikacji:
2005
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
kidney
vasculature
viral vectors
endothelium
recombinant adeno-associated virus
gene therapy
Opis:
Relatively successful elsewhere, gene delivery aimed at the vasculature and kidney has made very little progress. In the kidney, the hurdles are related to the unique structure–function relationships of this organ and in the blood vessels to a variety of, mostly endothelial, factors making the delivery of transgenes very difficult. Among gene-therapeutic approaches, most viral gene delivery systems utilized to date have shown significant practical and safety-related limitations due to the level and duration of recombinant transgene expression as well as their induction of a significant host immune response to vector proteins. Recombinant adeno-associated virus (rAAV) vectors appear to offer a vehicle for safe, long-term transgene expression. rAAV-based vectors are characterized by a relative non-immunogenicity and the absence of viral coding sequences. Furthermore, they allow for establishment of long-term latency without deleterious effects on the host cell. This brief review addresses problems related to transgene-delivery to kidney and vasculature with particular attention given to rAAV vectors. The potential for gene therapy as a strategy for selected renal and vascular diseases is also discussed.
Źródło:
Acta Biochimica Polonica; 2005, 52, 2; 293-299
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
pVAX1 plasmid vector-mediated gene transfer of soluble TRAIL suppresses human hepatocellular carcinoma growth in nude mice
Autorzy:
Zhang, Yan
Ma, Cun
Liu, Hua
Zhang, Xiu
Sun, Wen
Powiązania:
https://bibliotekanauki.pl/articles/1041078.pdf
Data publikacji:
2007
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
pVAX1
soluble TRAIL
naked DNA
gene therapy
hepatocellular carcinoma
Opis:
The extracellular domain of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) may function as a soluble cytokine to selectively kill various cancer cells without toxicity to most normal cells. We used a high-biosafety plasmid pVAX1 as a vector and constructed a recombinant plasmid expressing the extracellular domain (95-281 aa) of human TRAIL fused with signal peptides of human IgGγ, designated as pVAX-sT. Transduction of human BEL7402 liver cancer cells with pVAX-sT led to high levels of sTRAIL protein in the cell culture media and induced apoptosis. The therapeutic potential of pVAX-sT was then evaluated in the BEL7402 transplanted naked mouse model. Subsequent intratumoral administration of naked pVAX-sT resulted in the expression of soluble TRAIL in the sera and the tumor site, as well as effective suppression of tumor growth, with no toxicity to liver. In conclusion, the successful inhibition of liver cancer growth and the absence of detectable toxicity suggest that pVAX-sT could be useful in the gene therapy of liver cancer.
Źródło:
Acta Biochimica Polonica; 2007, 54, 2; 307-313
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Stem cells: applications, perspectives, misunderstandings
Autorzy:
Dulak, Józef
Powiązania:
https://bibliotekanauki.pl/articles/704245.pdf
Data publikacji:
2020
Wydawca:
Polska Akademia Nauk. Czytelnia Czasopism PAN
Tematy:
stem cells
cellular therapies
gene therapy
embryonic stem cells
induced pluripotent stem cells
Opis:
Stem cells exist and can do a lot. For several decades, bone marrow and umbilical cord blood transplants containing haematopoietic stem cells have been used in the treatment of blood diseases. Genetic modifications (gene therapy) of such cells help to cure complex immunodeficiencies and severe anaemias. The limbal stem cells taken from the eye and properly multiplied can regenerate the damaged cornea, and the epidermal stem cells help in the treatment of severe burns and some hereditary, severe skin diseases. Promising experimental research is under way on other uses of stem cells. However, these cells are appropriately selected, having real ability to differentiate into specialized cells whose malfunction is the cause of the disease. Therapeutic applications of stem cells are apparently limited to date. Meanwhile, the Internet is full of advertisements for supposedly miraculous treatments for almost any disease. Stem cells have become a modern synonym of the Holy Grail. A wonderful dish, transforming every drink into elixir of health, youth and long life. Stem cells from a single source, e.g., umbilical cord blood, or so-called cells, although without proven properties of stem cells, are offered in commercial private clinics as a panacea for autism, cerebral palsy, spina bifida, eye diseases, amyotrophic lateral sclerosis and dozens other disorders. Without justification for their action in these diseases, without convincing evidence of safety, but for a high fee. This article discusses stem cells and misunderstandings about including any cells among them. It draws attention to the real possibilities and confirmed uses of stem cells and presents the problems, doubts and dangers for patients associated with commercial offers of treatments using “stem” cells. The author cites the positions of scientific institutions and societies warning against premature commercialization of unjustified and potentially dangerous therapies
Źródło:
Nauka; 2020, 1
1231-8515
Pojawia się w:
Nauka
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Inhibition and regression of atherosclerotic lesions.
Autorzy:
Oka, Kazuhiro
Chan, Lawrence
Powiązania:
https://bibliotekanauki.pl/articles/1041405.pdf
Data publikacji:
2005
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
inflammation
atherosclerosis
helper-dependent adenovirus
lesion regression
inhibition of lesion progression
gene therapy
Opis:
Atherosclerosis, once believed to be a result of a slow, irreversible process resulting from lipid accumulation in arterial walls, is now recognized as a dynamic process with reversibility. Liver-directed gene therapy for dyslipidemia aims to treat patients who are not responsive to currently available primary and secondary prevention. Moreover, gene therapy strategies have also proved valuable in studying the dynamics of atherosclerotic lesion formation, progression, and remodeling in experimental animals. Recent results on the long-term effect of gene therapy suggest that hepatic expression of therapeutic genes suppresses inflammation and has profound effects on the nature of the atherogenic process.
Źródło:
Acta Biochimica Polonica; 2005, 52, 2; 311-319
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Zastosowanie form liposomalnych substancji
The use of liposomal forms of substances
Autorzy:
Słomczyńska, Patrycja
Paradowska, Katarzyna
Powiązania:
https://bibliotekanauki.pl/articles/31339065.pdf
Data publikacji:
2024-05-02
Wydawca:
Wydawnictwo Naukowe Medyk sp. z o.o.
Tematy:
liposome
drug delivery system
gene therapy
cosmetics
liposom
nośniki substancji leczniczych
terapia genowa
kosmetyki
Opis:
Liposomes are used as carriers of active compounds in various industries, such as pharmaceuticals, cosmetics, and food. Liposomal delivery systems of active substances play a significant role in the design of therapeutic formulations to improve therapeutic agents. The main goals of using preparations in liposomal form are to reduce toxicity and increase accumulation at the target site. This method of administering the active substance ensures greater safety and effectiveness of drug delivery, particularly with antiviral, antifungal, and antimicrobial properties. Liposomes can be used in gene therapy to precisely administer lower concentrations of medicinal substances to cells compared to non-liposomal counterparts. Liposomes have various applications in immunology, dermatology, and cancer therapy. Specifically, in cosmetology, innovative anti-aging, vitamin, and regenerating products for the deep layers of the epidermis can be developed using these structures. This article provides a brief overview of the structure and types of liposomes, which have great potential as carriers of active substances in medicinal and cosmetic products. The discussion included examples of the use of liposomes in medicine, such as anti-cancer, anti-psoriatic therapy, and anesthesiology. Additionally, the use of liposomes in cosmetology was discussed, specifically in products with anti-aging and antioxidant properties.
Liposomy jako nośniki aktywnych związków znalazły zastosowanie w kilku gałęziach przemysłu, m.in. farmaceutycznym, kosmetycznym czy spożywczym. Liposomowe systemy dostarczania substancji aktywnych pełnią znaczącą rolę w projektowaniu preparatów leczniczych w celu ich ulepszenia. Zmniejszenie toksyczności i zwiększenie akumulacji w miejscu docelowym to główne cele zastosowania preparatów w formie liposomalnej. Taka forma podawania substancji czynnej zapewnia większe bezpieczeństwo i skuteczność podawania leków, m.in. o działaniu przeciwwirusowym, przeciwgrzybiczym czy przeciwdrobnoustrojowym. Możliwości wykorzystania liposomów w terapii genowej pozwalają na precyzyjne podanie do komórek mniejszych stężeń substancji leczniczych w porównaniu do ich nieliposomalnych odpowiedników. Obecne zastosowania liposomów obejmują immunologię, dermatologię i terapię nowotworów. W kosmetologii stanowią innowacyjne produkty przeciwstarzeniowe, witaminowe oraz regenerujące głębokie warstwy naskórka. W artykule przedstawiono krótką charakterystykę budowy i rodzajów poznanych liposomów, które wykazują duży potencjał zastosowania tych struktur jako nośników substancji aktywnych w produktach leczniczych i kosmetycznych. Omówiono także przykłady zastosowań liposomów w medycynie w terapii przeciwnowotworowej, przeciwłuszczycowej czy anestezjologii oraz w kosmetologii w produktach o działaniu anti-ageing i antyoksydacyjnym.
Źródło:
Lek w Polsce; 2024, 394, 3; 39-47
2353-8597
Pojawia się w:
Lek w Polsce
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Targeting site-specific chromosome integration.
Autorzy:
Nuno-Gonzalez, Patricia
Chao, Hsu
Oka, Kazuhiro
Powiązania:
https://bibliotekanauki.pl/articles/1041401.pdf
Data publikacji:
2005
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
adeno-associated virus
phage C31 integrase
helper-dependent adenovirus
hybrid vector
viral vector
gene therapy
Opis:
The concept of gene therapy was introduced with great promise and high expectations. However, what appeared simple in theory has not translated into practice. Despite some success in clinical trials, the research community is still facing an old problem: namely, the need for a vector that can deliver a gene to target cells without adverse events while maintaining a long-term therapeutic effect. Some of these challenges are being addressed by the development of hybrid vectors which meld two different viral systems to incorporate efficient gene delivery and large cloning capacity with site-specific integration. The two known systems that integrate genes into specific sites in mammalian genomes are the adeno-associated virus and phage integrases. Recent experiments with hybrid vectors incorporating both of these systems are encouraging. However, extensive research should be directed towards the safety and efficacy of this approach before it will be available for gene therapy.
Źródło:
Acta Biochimica Polonica; 2005, 52, 2; 285-291
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Use of HIV as a gene transfer vector
Autorzy:
Pluta, Krzysztof
Kacprzak, Magdalena
Powiązania:
https://bibliotekanauki.pl/articles/1040467.pdf
Data publikacji:
2009
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
Lentivirus
lentiviral vectors
AIDS
HIV-1 life cycle
viral-host protein interactions
gene therapy
animal transgenesis
cell engineering
Opis:
Despite the extensive research efforts over the past 25 years that have focused on HIV, there is still no cure for AIDS. However, tremendous progress in the understanding of the structure and biology of the HIV virus led to the development of safe and potent HIV-based transgene delivery vectors. These genetic vehicles are referred to as lentiviral vectors. They appear to be better suited for particular applications, such as transgene delivery into stem cells, compared to other viral- and non-viral vectors. This is because Lentivirus-based vectors can efficiently infect nondividing and slowly dividing cells. In the present review article, the current state of understanding of HIV-1 is discussed and the main characteristics that had an impact on vector design are outlined. A historical view on the vector concept is presented to facilitate discussion of recent results in vector engineering in a broader context. Subsequently, a state of the art overview concerning vector construction and vector production is given. This review also touches upon the subject of lentiviral vector safety and related topics that can be helpful in addressing this issue are discussed. Finally, examples of Lentivirus-based gene delivery systems and their applications are presented, with emphasis on animal transgenesis and human gene therapy.
Źródło:
Acta Biochimica Polonica; 2009, 56, 4; 531-595
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies